此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCT (DXACT)

2026年11月6日 更新者:Medical University Innsbruck

Prospective Imaging-based Assessment of Skeletal Deterioration After Kidney Transplantation Using DXA and HR-pQCT (DXACT Study)

The goal of this observational study is to learn how bone health changes during the first year after kidney transplantation in adults receiving their first kidney transplant.

The main questions it aims to answer are:

  • How many patients show a clinically relevant decline in bone density or bone structure within 12 months after transplantation?
  • Does a standard bone density scan (DXA) detect these changes as well as a high-resolution scan of bone structure (HR-pQCT)?

Participants will:

  • Have a DXA scan of the lower spine, hip and forearm and an HR-pQCT scan of the forearm and lower leg shortly after transplantation and again after 12 months. Participants followed up in Innsbruck may also have these scans after 6 months.
  • Give blood and urine samples at the same visits, taken together with routine blood tests whenever possible, for bone and mineral markers and storage in a biobank.

The study does not change any treatment. All treatment decisions remain with the patients' physicians.

研究概览

详细说明

Bone mineral density declines rapidly during the first 6-12 months after kidney transplantation, driven by glucocorticoid exposure, persistent chronic kidney disease-mineral and bone disorder (CKD-MBD) and changes in bone turnover. This period coincides with the highest fracture risk. DXA-scans provide areal bone mineral density only and cannot distinguish cortical from trabecular bone or assess microarchitecture, so it may underestimate early cortical deterioration. HR-pQCT measures volumetric bone mineral density, cortical and trabecular microarchitecture and, by finite element analysis, estimated bone strength.

DXACT is an investigator-initiated, prospective, single-centre observational cohort study at the Medical University of Innsbruck. Baseline clinical and laboratory assessment is performed 7 +/- 2 days and imaging 10 +/- 7 days after transplantation; assessments are repeated at 12 months, with an optional 6-month visit for participants followed locally. HR-pQCT is performed at the distal radius and distal tibia of the dominant side (contralateral side if a vascular access or implant is present); DXA at the lumbar spine (L1-L4), hip and distal radius (33%).

Clinically relevant skeletal deterioration is defined as a change exceeding the least significant change (LSC = 2.77 x precision CV) of the respective modality and parameter. Laboratory assessments include parathyroid hormone, 25-hydroxy- and 1,25-dihydroxyvitamin D, calcium, phosphate, P1NP, bone-specific alkaline phosphatase, TRAP5b, CTX, osteocalcin and osteoprotegerin. EDTA plasma and urine are stored in a pseudonymised biobank at -80 °C.

Analyses are primarily descriptive and exploratory. Planned analyses include agreement and discordance between DXA- and HR-pQCT-based classification, associations of imaging changes with biochemical markers and clinical factors (age, sex, dialysis vintage, cumulative glucocorticoid dose, rejection, graft function), and comparison by graft function at 12 months. Incident fragility fractures beyond 12 months may be retrieved from routine clinical records without further participant contact.

研究类型

观察性的

注册 (估计的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Tyrol
      • Innsbruck、Tyrol、奥地利、6020
        • 招聘中
        • Medical University of Innsbruck, Department of Internal Medicine IV, Nephrology and Hypertension
        • 接触:
        • 接触:
        • 首席研究员:
          • Andreas Kronbichler, MD, PhD
        • 副研究员:
          • Clemens Untersulzner, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adult recipients of a first kidney transplant (living or deceased donor) treated at the Medical University of Innsbruck, Austria, who are approached by the study team within 10 days after transplantation.

描述

Inclusion Criteria:

  • Age 18 years or older at the time of kidney transplantation
  • First kidney transplantation (living or deceased donor)
  • Ability and willingness to provide written informed consent
  • Enrolment possible within 10 days after kidney transplantation
  • Clinical stability sufficient to undergo imaging procedures

Exclusion Criteria:

  • Previous kidney transplantation
  • Prior or ongoing treatment with antiresorptive or osteoanabolic therapies (e.g. bisphosphonates, denosumab, teriparatide) at the time of transplantation
  • Conditions precluding reliable bone imaging, including metal implants at the measurement sites
  • Contraindications to HR-pQCT or DXA
  • Inability to undergo imaging due to physical or technical limitations
  • Known metabolic bone diseases unrelated to chronic kidney disease-mineral and bone disorder (CKD-MBD)
  • Any condition that, in the opinion of the investigator, would interfere with study participation, data quality or protocol adherence

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Kidney transplant recipients

Adults (18 years or older) who received a first kidney transplant (living or deceased donor) at the Medical University of Innsbruck and are enrolled within 10 days after transplantation.

Dual-energy X-ray absorptiometry of the lumbar spine (L1-L4), hip and distal radius (33%) and high-resolution peripheral quantitative computed tomography of the distal radius and distal tibia, performed at baseline (10 +/- 7 days after kidney transplantation) and at 12 months, with an optional 6-month visit. Imaging is used for research only; no treatment is assigned.

其他名称:
  • 双能X射线吸收法
  • High-resolution peripheral quantitative computed tomography

Blood and urine samples at each study visit, taken together with routine blood draws, for markers of bone and mineral metabolism and storage in a biobank.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of Participants With Clinically Relevant Skeletal Deterioration on HR-pQCT
大体时间:Baseline (10 +/- 7 days after transplantation) to 12 months

Deterioration exceeding the least significant change (LSC = 2.77 x precision CV) in at least one of cortical thickness, cortical porosity or finite element-derived failure load at the distal radius or distal tibia.

Baseline (10 +/- 7 days after transplantation) to 12 months
Proportion of Participants With Clinically Relevant Skeletal Deterioration on DXA
大体时间:Baseline (10 +/- 7 days after transplantation) to 12 months

Decrease in areal bone mineral density exceeding the site-specific least significant change at the lumbar spine (L1-L4), hip or distal radius (33%).

Baseline (10 +/- 7 days after transplantation) to 12 months

次要结果测量

结果测量
措施说明
大体时间
Change in Cortical Thickness
大体时间:Baseline to 12 months

Absolute (mm) and relative (%) change in cortical thickness at the distal radius and distal tibia measured by HR-pQCT.

Baseline to 12 months
Change in Cortical Porosity
大体时间:Baseline to 12 months

Absolute (percentage points) and relative change in cortical porosity at the distal radius and distal tibia measured by HR-pQCT.

Baseline to 12 months
Change in Total Volumetric BMD
大体时间:Baseline to 12 months

Absolute (mg HA/cm³) and relative (%) change in total volumetric bone mineral density at the distal radius and distal tibia measured by HR-pQCT.

Baseline to 12 months
Change in Cortical Volumetric BMD
大体时间:Baseline to 12 months

Absolute (mg HA/cm³) and relative (%) change in cortical volumetric bone mineral density at the distal radius and distal tibia measured by HR-pQCT.

Baseline to 12 months
Change in Trabecular Volumetric BMD
大体时间:Baseline to 12 months

Absolute (mg HA/cm³) and relative (%) change in trabecular volumetric bone mineral density at the distal radius and distal tibia measured by HR-pQCT.

Baseline to 12 months
Change in Trabecular Number
大体时间:Baseline to 12 months

Absolute (1/mm) and relative (%) change in trabecular number at the distal radius and distal tibia measured by HR-pQCT.

Baseline to 12 months
Change in Trabecular Thickness
大体时间:Baseline to 12 months

Absolute (mm) and relative (%) change in trabecular thickness at the distal radius and distal tibia measured by HR-pQCT.

Baseline to 12 months
Change in Trabecular Separation
大体时间:Baseline to 12 months

Absolute (mm) and relative (%) change in trabecular separation at the distal radius and distal tibia measured by HR-pQCT.

Baseline to 12 months
Change in Biochemical Markers of Bone and Mineral Metabolism
大体时间:Baseline to 12 months

Change in parathyroid hormone, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, calcium, phosphate, P1NP, bone-specific alkaline phosphatase, TRAP5b, CTX, osteocalcin and osteoprotegerin

Baseline to 12 months
Change in Estimated Bone Strength (Failure Load)
大体时间:Baseline to 12 months

Absolute and relative change in finite element-derived failure load (N) at the distal radius and distal tibia.

Baseline to 12 months
Change in Areal Bone Mineral Density
大体时间:Baseline to 12 months

Absolute and relative change in areal BMD (g/cm2) at the lumbar spine (L1-L4), total hip, femoral neck and distal radius (33%) measured by DXA.

Baseline to 12 months
Skeletal Changes by Graft Function
大体时间:12 months

Comparison of HR-pQCT and DXA changes between participants with eGFR >= 60 and < 60 mL/min/1.73 m2 (CKD-EPI 2021) at 12 months.

12 months

其他结果措施

结果测量
措施说明
大体时间
Discordance Between DXA and HR-pQCT Classification
大体时间:12 months

Proportion of participants classified differently by DXA and HR-pQCT, in particular stable DXA with deterioration on HR-pQCT.

12 months
Association of Dialysis Vintage With Skeletal Deterioration
大体时间:Baseline to 12 months

Pre-transplant dialysis duration (continuous; pre-emptive, < 12, >= 12 months) as predictor of imaging-derived skeletal changes.

Baseline to 12 months
Incident Fragility Fractures
大体时间:Up to 5 years after transplantation

Fragility fractures retrieved from routine clinical records without participant contact.

Up to 5 years after transplantation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Andreas Kronbichler, MD, PhD、Medical University Innsbruck

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月21日

初级完成 (估计的)

2029年12月31日

研究完成 (估计的)

2029年12月31日

研究注册日期

首次提交

2026年10月28日

首先提交符合 QC 标准的

2026年11月6日

首次发布 (实际的)

2026年11月13日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared publicly, as participant consent does not cover transfer to third parties. De-identified data may be made available by the study lead upon reasonable request, subject to approval by the ethics committee and data protection regulations.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅